Page 7 - PRESENTATION
P. 7
Background
• Despite, high disease control rates (65-75%), with 1st line platinum-based
chemotherapy, PFS and OS are short due to chemotherapy resistance
• In 2 nd line, outcomes are poor due to rapid disease progression; and only a
minority will respond to the immune checkpoint inhibitors (ICIs)
• Avelumab maintenance in patients who did not have disease progression on first
line has 2 main advantages
• Disease control from chemo gives time for ICI to work
• Initiating an ICI before rapid disease progression, permits more patients to
receive treatment
Powles T, ASCO 2020
